Ainos, Inc. (AIMD)
After hours:
- ACCESSWIRE
Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market
Study to evaluate clinical effectiveness of low-dose oral interferons in treating chronic gingivostomatitis in cats, building upon VELDONA's history in animal health since 1985 Clinical trials are expected to run for approximately ten months from ...
- ACCESSWIRE
Ainos Reports First Quarter 2024 Financial Results
Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024 US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ainos, Inc. (NASDAQ:AIMD, ...
- ACCESSWIRE
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
Proceeds for scaling up the company's VELDONA and AI Nose growth initiatives Convertible note convertible at $4.5 per share placed with existing shareholder SAN DIEGO, CA / ACCESSWIRE / May 7, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", ...
